共 50 条
- [41] Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL StudyBLOOD, 2009, 114 (22) : 384 - 385Fowler, NathanKahl, Brad S.Rosen, PeterMatous, JeffreyCashen, AmandaJacobs, SamuelLetzer, JeffreyAmin, BipinkumarWilliams, MichaelRoss, MaureenSmith, SonaliSaleh, AlfredShi, HongliangParasuraman, SudhaCheson, Bruce D.
- [42] Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL StudyJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (25) : 3389 - 3395Fowler, NathanKahl, Brad S.Lee, PeterMatous, Jeffrey V.Cashen, Amanda F.Jacobs, Samuel A.Letzer, JeffreyAmin, BipinkumarWilliams, Michael E.Smith, SonaliSaleh, AlfredRosen, PeterShi, HongliangParasuraman, SudhaCheson, Bruce D.
- [43] Systematic Literature Review of the Clinical Efficacy and Safety of Treatments in the Relapsed/Refractory Setting for Patients with Follicular Lymphoma or Marginal Zone LymphomaBLOOD, 2017, 130Monga, NeeravGarside, JamieO'Donovan, PeterQuigley, JoanPadhiar, AmieParisi, LoriTapprich, ChristophNastoupil, Loretta
- [44] Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular LymphomaCANCER, 2011, 117 (11) : 2442 - 2451Baiocchi, Robert A.Alinari, LapoLustberg, Mark E.Lin, Thomas S.Porcu, PierluigiLi, XiaobaiJohnston, Jeffrey S.Byrd, John C.Blum, Kristie A.
- [45] A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).CANCER RESEARCH, 2021, 81 (13)Long, MeixiaoWoyach, JenniferPinilla-Ibarz, JavierStephens, Deborah M.Cacovean, AlexFiaz, RanaGoldberg, ZelannaJagasia, MadanFinckenstein, Friedrich GrafFardis, MariaByrd, C.
- [46] Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphomaBLOOD ADVANCES, 2021, 5 (03) : 823 - 828Panayiotidis, PanayiotisFollows, George A.Mollica, LuiginaNagler, ArnonOzcan, MuhitSantoro, ArmandoStevens, DonTrevarthen, DavidHiemeyer, FlorianGarcia-Vargas, JoseChilds, Barrett H.Zinzani, Pier LuigiDreyling, Martin
- [47] Efficacy and Safety of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma in the Phase 2 ACE-LY-004 StudyBLOOD, 2017, 130Wang, MichaelRule, SimonZinzani, Pier LuigiGoy, AndreCasasnovas, Rene-OlivierSmith, Stephen D.Damaj, GandhiDoorduijn, Jeanette K.Lamy, ThierryMorschhauser, FranckPanizo, CarlosShah, BijalDavies, AndrewEek, RichardDupuis, JehanJacobsen, EricKater, Arnon P.Le Gouill, StevenOberic, LucieRobak, TadeuszCovey, ToddDua, RichaHamdy, AhmedHuang, XinIzumi, RaquelPatel, PritiSlatter, J. GregJurczak, Wojciech
- [48] A Phase II Study of Brentuximab Vedotin and Bendamustine for Relapsed/Refractory Follicular LymphomaBLOOD, 2024, 144 : 6318 - 6319Kaleka, GuneetMoskoff, BenjaminZafar, AneeqaEsteghamat, Naseem S.Abedi, MehrdadSocola, Francisco AndresHoeg, Rasmus T.Tuscano, Joseph M.
- [49] A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or Refractory TTPBLOOD, 2014, 124 (21)Foley, Stephen RonanRock, GailBarth, DavidArnold, Donald M.Webert, Kathryn E.Yenson, Paul R.Kelton, John G.Clark, William FosterLi, Lihua
- [50] Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trialNature Medicine, 2022, 28 : 325 - 332Nathan Hale FowlerMichael DickinsonMartin DreylingJoaquin Martinez-LopezArne KolstadJason ButlerMonalisa GhoshLeslie PopplewellJulio C. ChavezEmmanuel BachyKoji KatoHideo HarigaeMarie José KerstenCharalambos AndreadisPeter A. RiedellP. Joy HoJosé Antonio Pérez-SimónAndy I. ChenLoretta J. NastoupilBastian von TresckowAndrés José María FerreriTakanori TeshimaPiers E. M. PattenJoseph P. McGuirkAndreas L. PetzerFritz OffnerAndreas ViardotPier Luigi ZinzaniRam MalladiAiesha ZiaRakesh AwasthiAisha MasoodOezlem AnakStephen J. SchusterCatherine Thieblemont